Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q4 2018 · 10-K
Revenue$84.42M$84.42M+47.4% vs Q4 2017 Net Income-$140.90M-$140.90MN/M vs Q4 2017 EPS Diluted-$2.05-$2.05N/M vs Q4 2017 Operating Income-$139,363,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$142,623,000N/M Margins · derivedOperating margin-165.1%−124.7 pt vs Q4 2017
Net margin-166.9%−125.0 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 28, 2019 · 59 d after period end